Tapentadol, Buprenorphine, and Levorphanol for the Treatment of Neuropathic Pain: a Systematic Review.
Atypical opioid
Buprenorphine
Levorphanol
Neuropathic pain
Tapentadol
Journal
Current pain and headache reports
ISSN: 1534-3081
Titre abrégé: Curr Pain Headache Rep
Pays: United States
ID NLM: 100970666
Informations de publication
Date de publication:
25 Feb 2021
25 Feb 2021
Historique:
accepted:
29
12
2020
entrez:
25
2
2021
pubmed:
26
2
2021
medline:
3
11
2021
Statut:
epublish
Résumé
The objective of this systematic review is to present the available evidence for the utilization of the atypical opioids tapentadol, buprenorphine, and levorphanol for the treatment of neuropathic pain. In total, 1619 articles were retrieved of which 10 studies were included. Of 5 included studies pertaining to tapentadol, 4 studies show tapentadol monotherapy to be effective for the treatment of diabetic peripheral neuropathy or chronic, radiating low back pain. Of the 3 studies included for buprenorphine, only one was a randomized controlled trial found not to have a statistically significant reduction in pain with TD buprenorphine likely due to very high withdrawal rates during the trial. Only 2 case reports were included from the available literature for levorphanol providing low-quality anecdotal evidence. The role of tapentadol, buprenorphine, and levorphanol for neuropathic pain conditions requires robust research including randomized controlled trials to evaluate their efficacy and safety.
Identifiants
pubmed: 33630185
doi: 10.1007/s11916-020-00934-z
pii: 10.1007/s11916-020-00934-z
doi:
Substances chimiques
Analgesics, Opioid
0
Levorphanol
27618J1N2X
Buprenorphine
40D3SCR4GZ
Tapentadol
H8A007M585
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM